Publications
Detailed Information
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhu, Viola W. | - |
dc.contributor.author | Lin, Yen-Ting | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Loong, Herbert H. | - |
dc.contributor.author | Nagasaka, Misako | - |
dc.contributor.author | To, Hao | - |
dc.contributor.author | Ang, Yvonne Li-En | - |
dc.contributor.author | Ock, Chan-Young | - |
dc.contributor.author | Tchekmedyian, Nishan | - |
dc.contributor.author | Ou, Sai-Hong Ignatius | - |
dc.contributor.author | Syn, Nicholas L. | - |
dc.contributor.author | Reungwetwattana, Thanyanan | - |
dc.contributor.author | Lin, Chia-Chi | - |
dc.contributor.author | Soo, Ross A. | - |
dc.date.accessioned | 2021-01-31T08:06:43Z | - |
dc.date.available | 2021-01-31T08:06:43Z | - |
dc.date.created | 2020-10-26 | - |
dc.date.created | 2020-10-26 | - |
dc.date.issued | 2020-09 | - |
dc.identifier.citation | Journal of Thoracic Oncology, Vol.15 No.9, pp.1484-1496 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.other | 113881 | - |
dc.identifier.uri | https://hdl.handle.net/10371/171813 | - |
dc.description.abstract | Introduction: Lorlatinib, a next-generation central nervous system-penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive (ALK+) NSCLC based on results from a phase 2 study. Methods: A real-world analysis was performed on ALK+ or ROS1-positive (ROS1+) patients with NSCLC enrolled in lorlatinib early or expanded access programs in Hong Kong, Singapore, South Korea, Taiwan, Thailand, and the United States. Results: A total of 95 patients with NSCLC (76 ALK+ and 19 ROS1+) were analyzed. Among ALK+ patients treated with less than two previous TKIs, two or more previous TKIs, and three or more previous TKIs, the objective response rates (ORR) and median progression-free survival (mPFS) were 42% (95% confidence interval [CI]: 26-59; n = 38) and not reached (NR) (95% CI: 4.5-NR; n = 45), 35% (95% CI: 22-49; n = 55) and 11.2 months (95% CI: 4.5-NR; n = 66), and 18% (95% CI: 4-43; n = 17) and 6.5 months (95% CI: 3.5-11.6; n = 21), respectively. The ORRs and mPFSs were 13% (95% CI: 0-53; n = 8) and 9.2 months (95% CI: 3.3-NR; n = 9) for patients treated with one second generation ALK TKI as the only ALK TKI received. For ROS1+ patients, ORRs and mPFSs were 41% (95% CI: 18- 67; n = 17) and 11.9 months (95% CI: 6.4-NR; n = 19). The intracranial ORRs were 35% (95% CI: 22-49) and 55% (95% CI: 23-83) for 52 ALK+ and 11 ROS1+ patients. mPFS was 9.3 months (95% CI: 1.0-NR; n = 13) for patients with leptomeningeal carcinomatosis. No new safety signals were noted. Conclusion: Lorlatinib exhibited meaningful activity in TKIrefractory ALK+ or ROS1+ patients with NSCLC enrolled in early or expanded access programs. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1016/j.jtho.2020.04.019 | - |
dc.citation.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.wosid | 000566479100015 | - |
dc.identifier.scopusid | 2-s2.0-85086020844 | - |
dc.citation.endpage | 1496 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 1484 | - |
dc.citation.volume | 15 | - |
dc.identifier.sci | 000566479100015 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CRIZOTINIB | - |
dc.subject.keywordAuthor | Lorlatinib | - |
dc.subject.keywordAuthor | Expanded access | - |
dc.subject.keywordAuthor | TKI-refractory | - |
dc.subject.keywordAuthor | ALK | - |
dc.subject.keywordAuthor | ROS1 | - |
dc.subject.keywordAuthor | NSCLC | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.